Completed
PHASE3
INTERVENTIONAL
NCT04657016
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
OTHER
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change From Baseline in Body Weight
TimeFrame:
Baseline, 72 Weeks
Description:
Percent change from baseline in body weight. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).
Measure:
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction
TimeFrame:
Week 72
Description:
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression model using imputed data with baseline body weight, Analysis Country, Sex, Treatment as factors.
Trial Information
NCT ID
NCT04657016
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025